Last quarter (Q4 2023), Capricor Therapeutics's total revenue was $12.09M, an increase of 1159.30% from the same quarter last year. In Q4, Capricor Therapeutics's net income was $-762.10K. See Capricor Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 25.18M	$ 25.18M	$ 2.55M	$ 244.90K	$ 310.25K	$ 1.01M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 22.19M	$ 25.18M	$ 2.55M	-	-	-
Operating Expense	$ 49.26M	$ 49.26M	$ 32.25M	$ -21.18M	$ 14.00M	$ 8.74M
Operating Income	$ -27.09M	$ -24.08M	$ -29.70M	$ -21.21M	$ -13.69M	$ -7.73M
Net Non Operating Interest Income Expense	-	-	-	$ 318.16K	-	-
Other Income Expense	$ -4.78M	$ -1.79M	$ -677.85K	$ -842.66K	$ 32.94K	$ 92.07K
Pretax Income	$ -22.24M	$ -22.24M	$ -29.02M	$ -20.05M	$ -13.66M	$ -7.64M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -22.30M	$ -22.29M	$ -29.02M	$ -20.05M	$ -13.66M	$ -7.64M
Basic EPS	$ -0.87	$ -0.83	$ -1.18	$ -0.87	$ -0.88	$ -2.06
Diluted EPS	$ -0.87	$ -0.83	$ -1.18	$ -0.87	$ -0.88	$ -2.06
Basic Average Shares	$ 107.11M	$ 26.78M	$ 24.55M	$ 23.09M	$ 15.57M	$ 3.71M
Diluted Average Shares	$ 107.11M	$ 26.78M	$ 24.55M	$ 23.09M	$ 15.57M	$ 3.71M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 49.26M	$ 49.26M	$ 32.25M	$ -21.18M	$ 14.00M	$ 8.74M
Net Income From Continuing And Discontinued Operation	$ -22.29M	$ -22.29M	$ -29.02M	$ -20.05M	$ -13.66M	$ -7.64M
Normalized Income	$ -11.40M	$ -17.56M	$ -22.88M	-	$ -13.69M	$ -7.73M
Interest Expense	-	-	-	-	-	-
EBIT	$ -22.24M	$ -22.24M	$ -29.00M	$ -20.05M	$ -13.69M	$ -7.73M
EBITDA	$ -21.17M	$ -21.17M	$ -28.47M	$ -19.81M	$ -13.55M	$ -7.56M

Currency in USD

Capricor Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing